Radiotherapy after breast-conserving surgery for patients with breast cancer is the standard treatment modality for early-stage breast cancer.Due to advances in imaging,surgery,and molecular pathology,downgrading of radiotherapy or even reasonable exemption from radiotherapy can be performed in low-risk patients with breast cancer to minimize the adverse effects of radiotherapy.This article reviews the evolutionary process of radiotherapy downgrading in breast cancer and the role of relevant pathological tests and genetic tests in assessing the prognosis of patients with breast cancer in radiotherapy,and discusses relevant trials on patients with hormone receptor-positive breast cancer combining multiple molecular tests for exemption from radiotherapy to identify patient groups that can be safely exempted from radiotherapy after breast-conserving surgery using available tumor biology and molecular predictions.
关键词
乳腺癌/保乳术后/放疗降级/分子检测/预后/进展
Key words
Breast cancer/Breast-conserving surgery/Radiation de-escalation/Molecular diagnostic techniques/Prognosis/Progress
维普
万方数据